Skip to main content
. 2019 Aug 21;5(1):120–126. doi: 10.1016/j.adro.2019.07.011

Figure 3.

Figure 3

Superficial dose versus patient: in vivo superficial dose measurements made with optically stimulated luminescence detectors for the 11 patients in the study and on the Rando phantom treated with tangential fields on the Halcyon, TrueBeam with and without bolus and with bolus applied on alternate days. The boxes represent the range of data from the 25% to the 75% percentile and whiskers are drawn to the furthest observations not considered outliers (outliers defined as >1.5 × range).